Shindler D M, Palmeri S T, Antonelli T A, Sleeper L A, Boland J, Cocke T P, Hochman J S
UMDNJ-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.
J Am Coll Cardiol. 2000 Sep;36(3 Suppl A):1097-103. doi: 10.1016/s0735-1097(00)00877-9.
We sought to examine the role of diabetes mellitus in cardiogenic shock (CS) complicating acute myocardial infarction (AMI) in the SHOCK Trial Registry.
The characteristics, outcomes and optimal treatment of diabetic patients with CS complicating AMI have not been well described.
Baseline characteristics, clinical and hemodynamic measures, treatment variables, shock etiologies and comorbid conditions were compared for 379 diabetic and 784 nondiabetic patients. Logistic regression was used to examine the association between diabetes and in-hospital mortality, after adjustment for baseline differences.
Diabetics were less likely than nondiabetics to undergo thrombolysis (28% vs. 37%; p = 0.002) or attempted revascularization (40% vs. 49%; p = 0.008). The survival benefit for diabetics selected for percutaneous or surgical revascularization (55% vs. 19% without revascularization) was similar to that for nondiabetics (59% vs. 25%). Overall unadjusted in-hospital mortality was significantly higher for diabetics (67% vs. 58%; p = 0.007), but diabetes was only a borderline predictor of mortality after adjustment for baseline and treatment differences (odds ratio for death, 1.36; 95% confidence interval, 1.00 to 1.84; p = 0.051).
Diabetics with CS complicating AMI have a higher-risk profile at baseline, but after adjustment, diabetics have an in-hospital survival rate that is only marginally lower than that of nondiabetics. Diabetics who undergo revascularization derive a survival benefit similar to that of nondiabetics.
我们试图在SHOCK试验注册研究中探讨糖尿病在并发急性心肌梗死(AMI)的心源性休克(CS)中的作用。
糖尿病患者并发AMI的CS的特征、结局及最佳治疗方法尚未得到充分描述。
比较了379例糖尿病患者和784例非糖尿病患者的基线特征、临床和血流动力学指标、治疗变量、休克病因及合并症。在对基线差异进行校正后,采用逻辑回归分析来研究糖尿病与院内死亡率之间的关联。
糖尿病患者接受溶栓治疗(28%对37%;p = 0.002)或尝试血管重建术(40%对49%;p = 0.008)的可能性低于非糖尿病患者。接受经皮或外科血管重建术的糖尿病患者的生存获益(55%对未行血管重建术的19%)与非糖尿病患者相似(59%对25%)。总体未经校正的糖尿病患者院内死亡率显著更高(67%对58%;p = 0.007),但在对基线和治疗差异进行校正后,糖尿病只是死亡率的一个临界预测因素(死亡比值比为1.36;95%置信区间为1.00至1.84;p = 0.051)。
并发AMI的CS的糖尿病患者在基线时具有更高的风险特征,但校正后,糖尿病患者的院内生存率仅略低于非糖尿病患者。接受血管重建术的糖尿病患者获得的生存获益与非糖尿病患者相似。